|

Incremental Value of Magnetic Resonance Imaging in Selection of Pancreatic Cancer Patients for Surgery

RECRUITINGN/ASponsored by University of Aarhus
Actively Recruiting
PhaseN/A
SponsorUniversity of Aarhus
Started2022-08-30
Est. completion2027-12-01
Eligibility
Age18 Years – 99 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05428358

Summary

The aim of the study is to examine the incremental value of using magnetic resonance imaging (MRI) in addition to computed tomography (CT) in the diagnostic workup of pancreatic cancer patients.

Eligibility

Age: 18 Years – 99 YearsHealthy volunteers accepted
Inclusion criteria:

* Pancreatic cancer patients considered to have a locally resectable or borderline resectable tumor by the local hepato-pancreato-biliary multidisciplinary team board
* No liver metastases on CT
* At least 18 years old and able to provide informed consent
* Expected pancreatic ductal adenocarcinoma based on CT scan

Exclusion criteria:

* Metastatic disease
* Prior receipt of neoadjuvant chemotherapy or downstaging/-sizing treatment
* Comorbidity rendering major surgery unfeasible (inoperable)
* No informed consent
* Unable to undergo MRI (Kidney insufficiency (eGFR \< 60 ml/min/1.73 m2 body surface ar-ea); Claustrophobia; Cardiac pacemaker)
* Postoperative histology other than adenocarcinoma of pancreato-biliary origin.
* MRI with liver-specific contrast performed during standard workup.

Conditions6

CancerLiver CancerLiver DiseaseLiver MetastasesPancreatic CancerPancreatic Neoplasm

Browse More Trials

Cancer trialsLiver Disease trialsLiver Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.